The generic version of Gvoke Hypopen may become available after 22nd April 2036, based on the expiry date of the last patent. The potential release date of Gvoke Hypopen generic is determined by the drug patents held by Xeris.
Gvoke Hypopen is used primarily for the treatment of severe hypoglycemia. The active ingredient, glucagon, functions to increase blood sugar levels, effectively combating the symptoms of hypoglycemia.
Gvoke Hypopen is protected by 2 patents. The last of these, titled 'Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents', expires on 22nd April 2036. The potential release date for Gvoke Hypopen generic is tied to this patent. Below are the details of the patents: